The Patent Finder

Orexo AB

15 patents currently held · Updated Nov 22, 2026
16 more in force are now held by other companies
Held is read from USPTO's recorded assignments; a transfer never recorded there does not appear.
2
Ending by 2030
Apr 2027
Next term end

When these terms end

Held patents by the year their term ends
20262027202820292030203120322033203420352036203720382039204020412042204320442045

Fee deadlines

Maintenance fees fall due 3.5, 7.5 and 11.5 years after grant. A missed fee ends a patent at the end of the six month grace period that follows, not on the due date.
  • 1 fee due Feb 28, 2027
    The maintenance fee for New Pharmaceutical Composition for Drug Delivery (US 11,737,980) comes due Feb 28, 2027. Unpaid by Aug 30, 2027, it lapses early.
  • 1 fee due Jul 30, 2027
    The maintenance fee for Pharmaceutical Composition for Nasal Delivery (US 11,883,392) comes due Jul 30, 2027. Unpaid by Jan 31, 2028, it lapses early.
  • 1 fee due Aug 23, 2027
    The maintenance fee for Pharmaceutical formulations useful in the treatment of insomnia (US 9,265,720) comes due Aug 23, 2027. Unpaid by Feb 23, 2028, it lapses early.
  • 1 fee due Oct 16, 2027
    The maintenance fee for Pharmaceutical Composition Comprising Adrenaline (US 11,957,647) comes due Oct 16, 2027. Unpaid by Apr 17, 2028, it lapses early.
  • 2 fees due Nov 19 to 21, 2027 · next Nov 19

Which patents, and when each one lapses · Pro

Recent changes

Nothing was recorded against this company's patents in the last 90 days.

Patents held now

Soonest term end first. Each date below is computed on that patent's own page, which shows the rule, the adjustments and the fee history it was derived from.
Confidence:Highevery input resolvedMediumone input unresolvedLowtwo or more caveatsUSPTO recordfrom USPTO's bulk records, without the patent's file history
PatentTitleStatus Expires Confidence
US 9,597,281Pharmaceutical formulations useful in the treatment of insomnia
In force
 · USPTO record
In forceUSPTO record
US 9,265,720Pharmaceutical formulations useful in the treatment of insomnia
In force
 · USPTO record
In forceUSPTO record
US 10,653,690Pharmaceutical Composition for Nasal Delivery
In force
 · High confidence
In forceHigh confidence
US 10,729,687Pharmaceutical Composition for Nasal Delivery
In force
 · High confidence
In forceHigh confidence
US 10,898,480Pharmaceutical composition for nasal delivery
In force
 · USPTO record
In forceUSPTO record
US 11,883,392Pharmaceutical Composition for Nasal Delivery
In force
 · High confidence
In forceHigh confidence
US 12,268,684Pharmaceutical Composition for Nasal Delivery
In force
 · High confidence
In forceHigh confidence
US 11,737,980New Pharmaceutical Composition for Drug Delivery
In force
 · High confidence
In forceHigh confidence
US 12,357,573New Pharmaceutical Composition for Drug Delivery
In force
 · High confidence
In forceHigh confidence
US 12,138,259Method of controlling depression in subjects treated for opioid dependence
In force
 · USPTO record
In forceUSPTO record
10 of 15 patents shown.
Pro members see all 15.
Pro members: see all 15 patents
Also on record, not counted in the 15: 16 patents in force now held by others · 13 lapsed for an unpaid fee · 4 ended at full term. List them

Sources and methods

Compiled from the USPTO record, grants, published applications and recorded assignments, not yet reviewed by hand. How this record was built
Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.

Published applications

US patent applications published under this name that have not become patents. An application is published about eighteen months after its earliest filing; one that has not been published is in no public record.

2 pending · 9 abandoned · 15 no status recorded

Showing 1 to 10 of 26, newest filing first. An application has no patent term. A term is computed when and if it grants, and appears on that patent's own page. Where no title is shown, the bulk publication record carries none and this site holds no USPTO file history for that application.

ApplicationTitleFiledStatus
19/189,960New Pharmaceutical Device for Use in Intranasal AdministrationApr 25, 2025Pending
19/076,099Pharmaceutical Composition for Nasal DeliveryMar 11, 2025Abandoned
18/712,027Pharmaceutical Composition Comprising Biopharmaceutical Drug CompoundsNov 25, 2022Pending
16/939,717Pharmaceutical Composition for Nasal DeliveryJul 27, 2020Abandoned
15/701,300Sep 11, 2017No status recorded
15/609,374New Abuse-Resistant Pharmaceutical Composition for the Treatment of Opioid DependenceMay 31, 2017Abandoned
15/499,645New Abuse-Resistant Pharmaceutical Composition for the Treatment of Opioid DependenceApr 27, 2017Abandoned
15/355,140Abuse-Resistant Pharmaceutical Composition for the Treatment of Opioid DependenceNov 18, 2016Abandoned
15/261,571Abuse-Resistant Pharmaceutical Composition for the Treatment of Opioid DependenceSep 9, 2016Abandoned
14/755,091Jun 30, 2015No status recorded
10 of 26 applications shown.
Pro members see all 26 published applications.
Pro members: see all 26 applications
The Patent Finder CompaniesExpirationsCalculatorWatchlistPricing MethodologyCorrectionsLegalPrivacysupport@thepatentfinder.com Updated Nov 22, 2026 · includes USPTO assignment data published Nov 21, 2026, status data published Nov 22, 2026 and grant & fee data published Nov 17, 2026 (weekly) Part of 137 Finder · © 2026 137 Finder LLC · Sources cited